Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, 1855W. Taylor Street, Chicago, IL, USA.
Prog Retin Eye Res. 2010 May;29(3):208-48. doi: 10.1016/j.preteyeres.2010.01.002. Epub 2010 Jan 25.
In this article, we provide the results of experimental studies demonstrating that corneal avascularity is an active process involving the production of anti-angiogenic factors, which counterbalance the pro-angiogenic/lymphangiogenic factors that are upregulated during wound healing. We also summarize pertinent published reports regarding corneal neovascularization (NV), corneal lymphangiogenesis and corneal angiogenic/lymphangiogenic privilege. We outline the clinical causes of corneal NV, and discuss the angiogenic proteins (VEGF and bFGF) and angiogenesis regulatory proteins. We also describe the role of matrix metalloproteinases MMP-2, -7, and MT1-MMP, anti-angiogenic factors, and lymphangiogenic regulatory proteins during corneal wound healing. Established and potential new therapies for the treatment of corneal neovascularization are also discussed.
在本文中,我们提供了实验研究的结果,这些研究表明角膜无血管是一个涉及产生抗血管生成因子的主动过程,这些因子与在创伤愈合过程中上调的促血管生成/淋巴管生成因子相平衡。我们还总结了有关角膜新生血管(NV)、角膜淋巴管生成和角膜血管生成/淋巴管生成特权的相关已发表报告。我们概述了角膜 NV 的临床病因,并讨论了血管生成蛋白(VEGF 和 bFGF)和血管生成调节蛋白。我们还描述了基质金属蛋白酶 MMP-2、-7 和 MT1-MMP、抗血管生成因子以及在角膜伤口愈合过程中淋巴管生成调节蛋白的作用。还讨论了治疗角膜新生血管的现有和潜在新疗法。